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Abstract
Background: Hyaluronic acid (HA) is well known to exert an anti-inflammatory effect during oral wound healing
and is commonly applied after tooth extraction. However, no double-blind randomized controlled study comparing
two hyaluronate mouthwash products has been conducted so far. The aim of this study was to comparatively
analyze the efficacy of Mucobarrier® and Aloclair® in terms of clinical symptoms.
Results: A total of 112 patients were randomly assigned to assess the degree of discomfort, pain reduction,
redness, burning sensation, and swelling between two groups on the day of surgery and 7 days later in a double
blind test, with a total 56 Aloclair patients and 56 Mucobarrier patients. There was no statistically significant
difference in the overall discomfort, degree of pain reduction, redness, burning sensation, and swelling between
the Mucobarrier and Aloclair groups.
Conclusion: The local application of hyaluronic acid mouth wash after wisdom tooth extraction is beneficial in
reducing overall discomfort and pain reduction, and the clinical utility of Mucobarrier® is no different from Aloclair®.
Trial registration: Institutional Review Board of Yonsei University College of Dentistry, 2-2018-0036. Registered 10
September 2018—prospectively registered, https://eirb.yuhs.ac/
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Background
The surgical extraction of wisdom teeth is one of the
most common procedures in oral surgery. Numerous
complications and sequelae can develop which nega-
tively affect patients’ quality of life such as pain, swelling,
bleeding, laceration of gingiva or oral mucosa, and tris-
mus [1, 2]. Steroid agents, as well as the application of
hyaluronic acid, are known to be effective in minimizing
these discomforts [2].
Hyaluronic acid (HA) is a polysaccharide of the extracel-
lular matrix found in various body tissues including con-
nective tissue, epithelium, and nerve tissues. HA can be
used safely in medicine because it is nonimmunogenic
and nontoxic [3]. It plays an important role in wound
healing through accumulation on the wound area, reinfor-
cing angiogenesis and suppressing the growth of fibro-
blasts by absorbing free radicals, thereby reducing scar
formation [4]. HA also contributes to maintaining the
constancy of the epidermis by maintaining osmotic pres-
sure; in addition, its many charged branches can reduce
pain by retaining a large amount of moisture [5]. Previous
studies of patients with recurrent apnea stomatitis found
that the pain in the group with hyaluronic acid was signifi-
cantly reduced [6, 7]. A study of pain control after CO2
laser surgery also showed reduced pain in the group to
which hyaluronic acid was applied [8]. Hyaluronic acids
are also used in the dental field in the form of gargle solu-
tion and are known to be particularly effective in wound
healing and pain control.
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The purpose of this clinical trial is to investigate
whether there is any benefit in local application of HA
solution (Mucobarrier® and Aloclair®) in wound healing
and pain control after extraction of wisdom teeth and to
prove the clinical effectiveness of Mucobarrier® is not in-
ferior to Aloclair® through a non-inferiority test. To the
best of our knowledge, this study comprises largest co-
hort group of patients who went under impacted third
molar extraction and also is the first study which exe-
cuted double-blind randomized control trial.
Methods
Patients
Patients who visited the Department of Oral and Max-
illofacial Surgery of Yonsei University Dental Hospital
from January 2019 to January 2020 were investigated.
This study was reviewed and approved by the Institu-
tional Review Board of Yonsei University College of
Dentistry (approval number 2-2018-0036).
The initial number of patients was 116, a 10% dropout
rate resulting in a total of 104 people, including 52 of
the Aloclair® group and 52 of the Mucobarrier® group.
Adults aged 19 or older who required surgical extraction
of wisdom tooth, who had voluntarily decided to partici-
pate in this clinical trial, and who could participate for
the entire pre-clinical period were chosen as study par-
ticipants. Pregnant or breastfeeding women and those
who did not understand the research were excluded
from the study.
Of the 116 recruited participants, four were excluded
due to follow-up loss. The final number of participants
was 112, 56 assigned to the Aloclair® group and 56 to
the Mucobarrier® group (Fig. 1).
Materials
Mucobarrier® and Aloclair® are oral prophylactic agents
containing hyaluronic acid and are made up of similar
ingredients. To prevent the test subjects from distin-
guishing the products, no product name was visible on
the container, nor was the agent visible inside (Fig. 2).
Patient assignment
The order of assignment was decided based on a
randomization of the registration numbers of the test
subjects performed using a computerized random alloca-
tion program; neither the test subjects nor experi-
menters were able to know which product had been
applied.
Patient evaluation
The degree of pain, burning sensation, redness, and
swelling on the day of the extraction was evaluated.
Data analysis and statistics
As this study is prospective, we evaluated differences in
the therapeutic effects between the two groups by divid-
ing the total 112 patients into 56 Aloclair® group and 56
Mucobarrier® group in a double-blind randomized
Fig. 1 Patient disposition
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control trial. The statistical analysis was done using R
version 3.6.3 (R Foundation, Vienna, Austria).
Results
This prospective study compared the therapeutic effects
of two HA products on individuals assigned to test and
control groups. Among a total 112 people (45 males and
67 females), 56 were assigned to the Aloclair® group and
56 to the Mucobarrier® group. Ages ranged from 18 to
71, with median age 29.5 and average age 32.0 (Table 1).
Overall discomfort, pain relief, burning sensation, red-
ness, and swelling were evaluated immediately after sur-
gery and 1 week after surgery. A visual analog scale was
used to assess the amount of pain, and there were no
statistically significant differences in overall discomfort,
pain relief, burning sensation, or swelling between the
two groups (Tables 2 and 3).
Discussion
After extraction of the wisdom tooth, complications such
as pain, redness, swelling, and burning sensation always
accompany though in varying degrees. Many studies have
attempted to minimize these, and hyaluronic acid has
been reported to have a positive effect on surgical wound
healing as well as on intraoral wound healing and pain re-
lief [9, 10]. Nolan et al. [7] said that HA can reduce pain
in the wound through barrier formation. HA itself has a
very high osmotic pressure, which allows it to maintain
sufficient moisture around damaged tissue during inflam-
matory reaction, thus stabilizing the wound and helping
cell migration and proliferation.
A previous study on the treatment of oral mucosa with
Aloclair after chemotherapy or radiation therapy found
that it soothes irritated tissue and reduces pain by forming
a protective membrane over oral mucosa. The main com-
ponents of Aloclair are purified water, maltodextrin,
propylene glycol, polyvinyl pyrrolidone (a hydrophilic
polymer which hydrates tissue, thus accelerating wound
healing in animal models and human wound), sodium
hyaluronic acid (which occurs naturally in body, forms
mucous, and thus hydrates mucous membranes while act-
ing as coating material on membranes), and glycyrrhetinic
acid (licorice extract, a cyclo-oxygenase inhibitor that me-
diates healing through antibacterial properties) [11].
Fig. 2 Hyaluronic acid products. a Mucobarrier®. b Aloclair®
Table 1 Demographic factors of participants
Factor Aloclair (N = 56) Mucobarrier (N = 56) N (percentage)
Age
Young adult (18–30 years) 28 29 57 (50.9%)
Middle adult (31–50 years) 20 23 43 (39.1%)
Young adult (> 56 years) 7 3 10 (9.1%)
Gender
Male 25 19 44 (40.0%)
Female 30 36 66 (60.0%)
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The main ingredients of Mucobarrier are sodium hya-
luronic acid and a trace amount of aloe, which is known
to have anti-inflammatory and antioxidant properties.
Visualized analog scale (VAS), a simple method of self-
assessment of subjective sensations, including pain, was
used to measure the degree of pain in this study [12]. It is
widely regarded as a valid method of quantitatively meas-
uring pain and has been used to study pain and inflamma-
tion after extraction of the third molar and to measure
pain of patients after oral mucosa biopsy [13, 14]. Al-
though many of the variables such as threshold for pain,
mental status on the day of operation, and emotional state
constitute subjective criteria and thus limitations of the
study, we interpreted the pain relief effect of hyaluronic
acid as valid because the only ingredient in common be-
tween Mucobarrier and Aloclair is hyaluronic acid and
there was definite pain reduction in both groups.
This study found no statistically significant difference
between Mucobarrier and Aloclair in terms of general
discomfort or pain relief nor any statistically significant
difference in local heat, redness, or swelling.
Reasons for the lack of significant differences between
the two groups are as follows. First, this study compared
the clinical symptoms on the day of extraction and a
week later, an interval which is too long considering that
clinical symptoms of postoperative inflammatory reac-
tions reach their peak after 1 or 2 days and generally
subside within a week. Thus, a week after surgery is im-
portant when considering the relevant factors affecting
the early stages of wound healing [15]. However, oral
mucosa receives a more abundant blood supply com-
pared to other parts of the body and wounds heal faster
than in other parts of the body. As primary healing oc-
curs within 2 weeks in most cases, the 1-week interval of
evaluation in this study could not fully reflect the entire
healing process. This may have contributed to our out-
come. Nolan et al. applied HA on aphthous stomatitis
ulcerative lesion and followed up every day to observe
the differences between the HA and placebo group.
There were significant differences on day 4, suggesting
that significant differences might be seen during the first
week after surgery.
Furthermore, like previous studies including HA, this
study was based on limited sample sizes and designed
without negative control. Although previous study about
discomfort after third molar surgery without any other
agents applied showed higher percentage of discomfort
compared to the result of our study with HA applied,
additional studies of different design and with more par-
ticipants including negative control would yield more re-
liable contrastive research [16].
Conclusions
Based on this study, the local application of hyaluronic
acid solution after extraction of wisdom tooth is benefi-
cial for post-operative discomfort and pain reduction,
and the clinical effect of Mucobarrier® is not inferior to
Aloclair®.
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Table 2 Post-operative discomfort and pain
Group Aloclair (N = 56) Mucobarrier (N = 56) p
Subjective_overall_discomfort 0.538
1. Very good 9 (15.1%) 14 (23.6%)
2. Comfortable 35 (64.2%) 35 (63.6%)
3. Slight discomfort 11 (18.9%) 6 (10.9%)
4. Very uncomfortable 1 (1.9%) 1 (1.8%)
Pain reduction 5.0 [2.0;6.0] 5.0 [3.0;5.5] 0.804
“Minimal” refers to a noticeable state, but not apparent compared to the contralateral side
Table 3 Post-operative burning sensation, redness, and swelling
Group Aloclair (N = 56) Mucobarrier (N = 56) p
Burning sensation 1
1. Absent 49 (88.7%) 48 (87.3%)
2. Present 7 (11.3%) 8 (12.7%)
Redness 0.681
1. Absent 26 (45.3%) 27 (49.1%)
2. Minimal 20 (35.8%) 22 (38.2%)
3. Apparent 10 (18.9%) 7 (12.7%)
Swelling 0.936
1. Absent 23 (39.6%) 23 (40.0%)
2. Minimal 25 (45.3%) 26 (47.3%)
3. Apparent 8 (15.1%) 7 (12.7%)
“Minimal” refers to a noticeable state, but not apparent compared to the
contralateral side
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